Trial: 201905012

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Phase

I

Principal Investigator

Vij, Ravi

Disease Site

Multiple Myeloma

Learn more about this study at: clinicaltrials.gov